Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.7 USD | +3.09% | +1.92% | -6.21% |
Mar. 25 | Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran | CI |
Mar. 08 | Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.21% | 3.56B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.54% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |
- Stock
- Equities
- Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq
- News Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Vivo Capital Form Joint Venture to Expand Reach of Innovative Medicines in Greater China